Alpha Teknova, Inc. TKNO

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
36/100
Developing

About Alpha Teknova, Inc.

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab … Full TKNO analysis →

Competitive advantage assessment

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.78), suggesting sticky customer base.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.85), providing operational cushion.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 23.8th percentile with high volatility suggests weak pricing power or commoditized products.
  • ROIC Below WACC or Peers ROIC at 36.6th percentile suggests inefficient capital deployment.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
25

Where TKNO ranks in Drug Manufacturers - Specialty & Generic

Alpha Teknova, Inc. ranks #57 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 63%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

Moat scores for companies ranked near TKNO in Drug Manufacturers - Specialty & Generic
# Company Moat score Rating
53 BGM Group Ltd. BGM 37/100 Developing
54 Biofrontera Inc. BFRI 37/100 Developing
55 Biofrontera Inc. Warrants BFRIW 37/100 Developing
56 IM Cannabis Corp. IMCC 37/100 Developing
57 Alpha Teknova, Inc. TKNO 36/100 Developing
58 Universe Pharmaceuticals Inc UPC 36/100 Developing
59 Canopy Growth Corporation CGC 35/100 Developing
60 SCYNEXIS, Inc. SCYX 34/100 Developing
61 Cardiol Therapeutics Inc. CRDL 33/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How TKNO scores on the Corporate Default defenses

Pricing Power

Score 25 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 28 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 48 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 36 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 47 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 36 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding TKNO's moat

What is Alpha Teknova, Inc.'s moat score?

Alpha Teknova, Inc. (TKNO) scores 36 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #57 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 63%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Customer Stickiness (48/100) and its weakest is Pricing Power (25/100).

How does Alpha Teknova, Inc. compare with other Drug Manufacturers - Specialty & Generic companies?

Alpha Teknova, Inc. ranks #57 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are IM Cannabis Corp. (IMCC) at 37 just above it and Universe Pharmaceuticals Inc (UPC) at 36 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Alpha Teknova, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Alpha Teknova, Inc.?

The Corporate Default template measures 6 defenses, and TKNO scores: Pricing Power (25), Cost Advantage (28), Customer Stickiness (48), Capital Efficiency (36), Resilience (47), Scale & Market Position (36). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000